Until recently, the view that dietary vitamin K interferes with oral anticoagulant therapy was based on case reports and a few small experimental studies with extremely high vitamin K intake. In two recent studies the effect of dietary vitamin K on oral anticoagulation was systematically investigated [1, 2] . These studies showed that, even in patients on an average diet, changes in vitamin K intake affect anticoagulation. When patients decreased their vitamin K intake the International Normalized Ratio (INR) response was more pronounced than when vitamin K intake was increased [2] . Because changes are proportionally larger in people with a low average vitamin K intake, it is likely that the INR is more sensitive to a varying vitamin K intake in those individuals. Sconce et al. established that daily intake of vitamin K was indeed lower in patients with unstable anticoagulation than in stably anticoagulated patients [3] . Daily supplementation of low doses of vitamin K might thus be beneficial.
To safely start vitamin K supplementation in patients receiving oral anticoagulants, it is important to know the effect of low doses of vitamin K on the INR and on the dose of the anticoagulant drug. The dose-response relationship of vitamin K supplementation on the INR in healthy subjects who received a fixed dose of oral anticoagulants was established by Schurgers et al. [4] . They concluded that 100 lg of vitamin K daily did not significantly interfere with oral anticoagulant therapy. Consequently, Oldenburg suggested 100 lg vitamin K as a recommended supplementation dose in his editorial [5] . However, Kurnik et al. found that, in patients with a low vitamin K status, even daily supplement doses as low as 25 lg led to an important reduction of the INR [6] .
We performed a pilot study to determine the effect of escalating daily doses of vitamin K on the required dose of the anticoagulant drug phenprocoumon. We included patients from the Leiden Anticoagulation Clinic who took part in a program for self-management of anticoagulant treatment. The total study period was 9 weeks, in which the INR was measured at least 3 times a week with a CoaguCheck S coagulometer (Roche Diagnostics, Almere, Netherlands). Patients received vitamin K for 3 weeks. The first and last 3 weeks served as control periods. Five patients received 50 lg and 10 patients 100 lg of oil-based vitamin K1 (250 lg g )1
). The primary endpoint was the percentage change in phenprocoumon dose during and after vitamin K needed to keep the INR within therapeutic limits.
Supplementation of 50 lg vitamin K had little effect on the INR and therefore only slight dose-adjustments were made (mean dose increase after starting vitamin K 3% [95% confidence interval (CI95): )4% to 10%]. Supplementation of 100 lg resulted in a mean dose increase of 9% (CI95: 0-19%, Fig. 1 ). There was considerable inter-individual variability in response with dose adjustments ranging from )7% to 37%. In the three weeks of follow-up after the vitamin K was discontinued phenprocoumon doses were lowered to presubstitution values (mean change of )7%, CI95: )15% to 0%).
Our results show that daily supplementation up to 100 lg can be given without a relevant decrease in the INR, on the condition of frequent monitoring during and after the supplementation to allow timely dose adjustments. The acute phase response (APR) is a systemic response to local inflammatory processes elicited by infection and/or other types of tissue injury [1, 2] . It serves to limit the effect of damaging agents by inducing a largely cytokine-mediated series of systemic events, such as fever, altered metabolism, changes in concentrations of a series of blood proteins (acute phase proteins), and changes in vascular permeability and hematologic parameters. Mainly tumor necrosis factor (TNF)-a, interleukin (IL)-6 and IL-1 induce the changes in synthesis of acute phase proteins. Intravenous injection of endotoxin provides a highly controlled model to investigate the APR [3] . Studies of patients with sepsis and of in vivo endotoxin challenge of healthy subjects have shown that the APR promotes thrombin generation as reflected by an increased formation of thrombin-antithrombin complex and prothrombin fragment 1 + 2 [4] [5] [6] . Levels of the anticoagulant proteins; tissue factor pathway inhibitor, protein C and antithrombin are often decreased in patients exhibiting an APR, mainly because of increased consumption of these three proteins [4, 5] . In the model of human endotoxemia the levels of antithrombin and tissue factor pathway inhibitor are not or only slightly affected, whereas protein C levels decrease about 15% partly or wholly as a result of thrombin-catalyzed conversion of protein C to activated protein C [5, 7] . The anticoagulant protein, protein S is an essential cofactor to activated protein C in the inactivation of factors Va and VIIIa [8] . Effective enhancement of activated protein C-mediated inactivation of factor VIIIa by protein S requires the presence of FV. About 60% of protein S forms an 
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